<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7426546\results\search\disease\results.xml">
  <result pre="the recently emerging SARS-CoV-2 pandemic has attracted major attention to" exact="viral" post="diseases, in particular coronaviruses. In spite of alarming molecular"/>
  <result pre="biological properties in the context of our overall understanding of" exact="viral" post="diseases. Coronavirus coronavirus disease 2019 human coronavirus severe acute"/>
  <result pre="context of our overall understanding of viral diseases. Coronavirus coronavirus" exact="disease" post="2019 human coronavirus severe acute respiratory syndrome INTRODUCTION In"/>
  <result pre="of viral diseases. Coronavirus coronavirus disease 2019 human coronavirus severe" exact="acute" post="respiratory syndrome INTRODUCTION In March 2015, Bill Gates, the"/>
  <result pre="viral diseases. Coronavirus coronavirus disease 2019 human coronavirus severe acute" exact="respiratory" post="syndrome INTRODUCTION In March 2015, Bill Gates, the cofounder"/>
  <result pre="diseases. Coronavirus coronavirus disease 2019 human coronavirus severe acute respiratory" exact="syndrome" post="INTRODUCTION In March 2015, Bill Gates, the cofounder of"/>
  <result pre="next few decades, itâ€™s most likely to be a highly" exact="infectious" post="virus rather than a war,â€� Gates said. Gates repeatedly"/>
  <result pre="in 2020, when the World Health Organization declared the coronavirus" exact="disease" post="2019 (COVID-19)â€&quot;caused by the newly emerging SARS-CoV-2 virusâ€&quot;to be"/>
  <result pre="coronaviruses, which were temporarily in the spotlight when the severe" exact="acute" post="respiratory syndrome (SARS) disease emerged in China in 2002,3â€&quot;5"/>
  <result pre="which were temporarily in the spotlight when the severe acute" exact="respiratory" post="syndrome (SARS) disease emerged in China in 2002,3â€&quot;5 and"/>
  <result pre="were temporarily in the spotlight when the severe acute respiratory" exact="syndrome" post="(SARS) disease emerged in China in 2002,3â€&quot;5 and later"/>
  <result pre="in the spotlight when the severe acute respiratory syndrome (SARS)" exact="disease" post="emerged in China in 2002,3â€&quot;5 and later when the"/>
  <result pre="in China in 2002,3â€&quot;5 and later when the Middle East" exact="respiratory" post="syndrome (MERS) appeared in Saudi Arabia in 2012.6,7 These"/>
  <result pre="China in 2002,3â€&quot;5 and later when the Middle East respiratory" exact="syndrome" post="(MERS) appeared in Saudi Arabia in 2012.6,7 These outbreaks"/>
  <result pre="of investigators.8â€&quot;11 This was based on the wide range of" exact="viral" post="reservoirs and previous documentation of cross-species spread in veterinary"/>
  <result pre="SARS-CoV-2 virus in the context of our general understanding of" exact="viral" post="diseases. THE CORONAVIRUS SUBFAMILYâ€&quot;GENERAL FEATURES COVID-19 is caused by"/>
  <result pre="of spikes that project from the envelope and give the" exact="viral" post="particle the shape of a solar corona, inspiring the"/>
  <result pre="phosphoprotein, which forms a helical ribonucleoprotein core together with the" exact="viral" post="genome; the trimeric spike (S) glycoprotein, which mediates virion"/>
  <result pre="integral envelope (E) protein, which plays an important role in" exact="viral" post="envelope assembly. Certain coronaviruses also include the hemagglutinin-esterase (HE)"/>
  <result pre="Certain coronaviruses also include the hemagglutinin-esterase (HE) protein, which forms" exact="short" post="protrusions beneath the S protein spikes. All structural genes,"/>
  <result pre="third of the genome, while the other two-thirds encode the" exact="viral" post="non-structural proteins (NSPs), such as replication enzymes and additional"/>
  <result pre="cleavage of the polypeptide is essential for production of functional" exact="viral" post="proteins, drugs that target these proteinases have potential therapeutic"/>
  <result pre="RNA replication and transcription. Of note, the coronaviruses encode several" exact="viral" post="proteins with RNA-modifying or replication activities, including RNA-dependent RNA-polymerase"/>
  <result pre="potentially enable rapid genetic changes in coronaviruses. Accordingly, long-term coronavirus" exact="infection" post="in some animals, combined with high mutation and recombination"/>
  <result pre="a proofreading function during CoV replication is provided by the" exact="viral" post="protein ExoN and may balance between fidelity and misincorporation"/>
  <result pre="of CoV replication and thus promote high-level mutagenesis of the" exact="viral" post="genome that could drive virus extinction.15â€&quot;17 CORONAVIRUSES PATHOGENESIS Before"/>
  <result pre="associated with devastating outbreaks of severe diseases in livestock, mostly" exact="gastroenteritis" post="and bronchitis, affecting domestic animals including cattle, pigs, and"/>
  <result pre="animals including birds, snakes, mice, and bats.8 Human CoV (hCoV)" exact="infection" post="(Table 1) was first described in the 1960s and"/>
  <result pre="described in the 1960s and was primarily associated with mild" exact="upper" post="respiratory diseases (the â€œcommon coldâ€�) caused by hCoV-229E and"/>
  <result pre="in the 1960s and was primarily associated with mild upper" exact="respiratory" post="diseases (the â€œcommon coldâ€�) caused by hCoV-229E and hCoV-OC43.18â€&quot;20"/>
  <result pre="identified almost 40 years later: hCoV-HKU1, which was linked with" exact="chronic" post="pulmonary disease,21 and hCoV-NL63, which was associated with both"/>
  <result pre="almost 40 years later: hCoV-HKU1, which was linked with chronic" exact="pulmonary" post="disease,21 and hCoV-NL63, which was associated with both upper"/>
  <result pre="chronic pulmonary disease,21 and hCoV-NL63, which was associated with both" exact="upper" post="and lower respiratory tract disease in children and adults.22"/>
  <result pre="disease,21 and hCoV-NL63, which was associated with both upper and" exact="lower" post="respiratory tract disease in children and adults.22 In addition,"/>
  <result pre="and hCoV-NL63, which was associated with both upper and lower" exact="respiratory" post="tract disease in children and adults.22 In addition, hCoV-NL63"/>
  <result pre="which was associated with both upper and lower respiratory tract" exact="disease" post="in children and adults.22 In addition, hCoV-NL63 was associated"/>
  <result pre="in children and adults.22 In addition, hCoV-NL63 was associated with" exact="croup" post="in infants and young children. Interestingly, association of hCoV-NL63"/>
  <result pre="in infants and young children. Interestingly, association of hCoV-NL63 with" exact="Kawasaki disease," post="an inflammation of blood vessels that mostly occurs in"/>
  <result pre="Interestingly, association of hCoV-NL63 with Kawasaki disease, an inflammation of" exact="blood vessels" post="that mostly occurs in children, has been reported,23 yet"/>
  <result pre="common cold,26â€&quot;28 yet they have the potential to cause severe" exact="lower" post="respiratory tract infection in infants, in the elderly, and"/>
  <result pre="cold,26â€&quot;28 yet they have the potential to cause severe lower" exact="respiratory" post="tract infection in infants, in the elderly, and in"/>
  <result pre="they have the potential to cause severe lower respiratory tract" exact="infection" post="in infants, in the elderly, and in patients with"/>
  <result pre="to influenza virus.10 The three other hCoVs can infect the" exact="lower" post="respiratory tract and cause a severe acute respiratory syndrome"/>
  <result pre="influenza virus.10 The three other hCoVs can infect the lower" exact="respiratory" post="tract and cause a severe acute respiratory syndrome (SARS)."/>
  <result pre="can infect the lower respiratory tract and cause a severe" exact="acute" post="respiratory syndrome (SARS). The SARS-CoV was identified with the"/>
  <result pre="infect the lower respiratory tract and cause a severe acute" exact="respiratory" post="syndrome (SARS). The SARS-CoV was identified with the emergence"/>
  <result pre="the lower respiratory tract and cause a severe acute respiratory" exact="syndrome" post="(SARS). The SARS-CoV was identified with the emergence in"/>
  <result pre="SARS-CoV was identified with the emergence in 2002 of an" exact="atypical pneumonia" post="that resulted in a 10% mortality rate, and MERS-CoV"/>
  <result pre="was identified with the emergence in 2002 of an atypical" exact="pneumonia" post="that resulted in a 10% mortality rate, and MERS-CoV"/>
  <result pre="Table 1 Human Coronaviruses (hCoVs). Species Genus Year of Discovery" exact="Disease" post="Association Cellular Receptor hCoV-229E Alphacoronavirus 1966 Common cold, pneumonia"/>
  <result pre="Discovery Disease Association Cellular Receptor hCoV-229E Alphacoronavirus 1966 Common cold," exact="pneumonia" post="Human aminopeptidase N (APN) hCoV-OC43 Betacoronavirus 1967 Common cold,"/>
  <result pre="neurological dysfunction 9-O-acetylated sialic acid hCoV-SARS (SARS-CoV) Betacoronavirus 2003 Severe-acute" exact="respiratory" post="syndrome Angiotensin-converting enzyme 2 (ACE2) hCoV-NL63 Alphacoronavirus 2004 Common"/>
  <result pre="dysfunction 9-O-acetylated sialic acid hCoV-SARS (SARS-CoV) Betacoronavirus 2003 Severe-acute respiratory" exact="syndrome" post="Angiotensin-converting enzyme 2 (ACE2) hCoV-NL63 Alphacoronavirus 2004 Common cold,"/>
  <result pre="Angiotensin-converting enzyme 2 (ACE2) hCoV-NL63 Alphacoronavirus 2004 Common cold, pneumonia," exact="bronchiolitis" post="Angiotensin-converting enzyme 2 (ACE2) hCoV-HKU1 Betacoronavirus 2005 Common cold,"/>
  <result pre="bronchiolitis Angiotensin-converting enzyme 2 (ACE2) hCoV-HKU1 Betacoronavirus 2005 Common cold," exact="pneumonia" post="9-O-acetylated sialic acid hCoV-MERS (MERS-CoV) Betacoronavirus 2012 Severe-acute respiratory"/>
  <result pre="cold, pneumonia 9-O-acetylated sialic acid hCoV-MERS (MERS-CoV) Betacoronavirus 2012 Severe-acute" exact="respiratory" post="syndrome Dipeptidyl peptidase 4 (DPP4) HCoV-SARS-2 Betacoronavirus 2020 Severe-acute"/>
  <result pre="pneumonia 9-O-acetylated sialic acid hCoV-MERS (MERS-CoV) Betacoronavirus 2012 Severe-acute respiratory" exact="syndrome" post="Dipeptidyl peptidase 4 (DPP4) HCoV-SARS-2 Betacoronavirus 2020 Severe-acute respiratory"/>
  <result pre="respiratory syndrome Dipeptidyl peptidase 4 (DPP4) HCoV-SARS-2 Betacoronavirus 2020 Severe-acute" exact="respiratory" post="syndrome Angiotensin-converting enzyme 2 (ACE2) Both hCoV-229E and hCoV-NL63"/>
  <result pre="syndrome Dipeptidyl peptidase 4 (DPP4) HCoV-SARS-2 Betacoronavirus 2020 Severe-acute respiratory" exact="syndrome" post="Angiotensin-converting enzyme 2 (ACE2) Both hCoV-229E and hCoV-NL63 are"/>
  <result pre="ancestors, and passed to humans either directly or through an" exact="intermediate" post="host.8,30 Other examples of transmission across species barriers occurred"/>
  <result pre="for hCoV-NL63, SARS-CoV, MERS-CoV-2, and SARS-CoV-2 cellular tropism.33 Like other" exact="viral" post="receptors ACE2 is a cellular molecule which has an"/>
  <result pre="suggest potential therapeutic strategies. Development of animal models for SARS-CoV-2" exact="infection" post="is vital in providing comprehensive understanding of the pathogenic"/>
  <result pre="virus with no specific treatment and no vaccine. Identification of" exact="infection" post="among hospitalized patients is of high priority to prevent"/>
  <result pre="infection among hospitalized patients is of high priority to prevent" exact="nosocomial infection" post="and subsequent community transmission. Ideal diagnostic tests are highly"/>
  <result pre="among hospitalized patients is of high priority to prevent nosocomial" exact="infection" post="and subsequent community transmission. Ideal diagnostic tests are highly"/>
  <result pre="highly specific and sensitive, avoiding false-positive and false-negative outcomes, respectively." exact="Viral" post="infections can be diagnosed through the detection of viral"/>
  <result pre="specific and sensitive, avoiding false-positive and false-negative outcomes, respectively. Viral" exact="infections" post="can be diagnosed through the detection of viral antigens"/>
  <result pre="respectively. Viral infections can be diagnosed through the detection of" exact="viral" post="antigens or genomes by various methods, of which the"/>
  <result pre="which the most widely used is based on amplification of" exact="viral" post="genomic sequences. Indeed, SARS-CoV-2 testing is based on respiratory"/>
  <result pre="of viral genomic sequences. Indeed, SARS-CoV-2 testing is based on" exact="respiratory" post="specimens, either oropharyngeal, nasopharyngeal, or both, that undergo RNA"/>
  <result pre="out COVID-19 in suspected patients and may also track the" exact="infection" post="in those who were in contact with infected individuals."/>
  <result pre="rate.34 An alternative to nucleic acid detection is to identify" exact="viral" post="antigens, in particular those that are highly abundant, such"/>
  <result pre="IgG antibodies, have potential diagnostic implications. The antibody response to" exact="infection" post="takes days to weeks to be detectable. Therefore, these"/>
  <result pre="detectable. Therefore, these tests cannot be used to detect an" exact="acute" post="infection and will generally also be negative during the"/>
  <result pre="Therefore, these tests cannot be used to detect an acute" exact="infection" post="and will generally also be negative during the first"/>
  <result pre="modes of transmission, such as droplet infection, and predict the" exact="infection" post="spread. Populations at high risk for infection and severe"/>
  <result pre="and predict the infection spread. Populations at high risk for" exact="infection" post="and severe outcome, such as the elderly or individuals"/>
  <result pre="and severe outcome, such as the elderly or individuals with" exact="chronic" post="disease, can also be identified via epidemiologic investigation. Among"/>
  <result pre="identified via epidemiologic investigation. Among other parameters, the prediction of" exact="disease" post="spread is based on the basic reproductive number (R0)"/>
  <result pre="reduce R0, which is modulated by the time interval of" exact="viral" post="shedding, viral infectiousness, and the interface that mediates transmission"/>
  <result pre="which is modulated by the time interval of viral shedding," exact="viral" post="infectiousness, and the interface that mediates transmission between infected"/>
  <result pre="helps develop guidelines for prevention and containment. Sequence analysis of" exact="viral" post="genomes may also help tracking virus dissemination within a"/>
  <result pre="an ongoing outbreak, in particular when the number of asymptomatic" exact="infections" post="is high. Finally, research has shown that people become"/>
  <result pre="infections is high. Finally, research has shown that people become" exact="infectious" post="before any symptoms of illness appear, during the pre-symptomatic"/>
  <result pre="the pre-symptomatic incubation period, while others do not develop a" exact="disease" post="and remain asymptomatic. Asymptomatic individuals may be those in"/>
  <result pre="their ability to spread the virus is limited. However, because" exact="disease" post="symptoms are affected by the immune response, lack of"/>
  <result pre="response and does not necessarily correlate with high or low" exact="viral" post="loads. Either way, it is interesting to examine the"/>
  <result pre="interesting to examine the relationship between the severity of the" exact="disease" post="and the response of the innate, humoral and cellular"/>
  <result pre="cellular immune systems over time. Knowing the proportion of asymptomatic" exact="infections" post="and whether asymptomatic individuals are contagious and can spread"/>
  <result pre="masks and social distancing. ANTI-VIRAL TREATMENTS Drug treatment for most" exact="viral" post="diseases is limited, and relies primarily on symptomatic treatment"/>
  <result pre="for most viral diseases is limited, and relies primarily on" exact="symptomatic" post="treatment and supportive care with no attempt to impair"/>
  <result pre="safety. In addition, anti-viral drugs must be highly effective, as" exact="incomplete" post="inhibition of the virus infection may enable selection of"/>
  <result pre="drugs must be highly effective, as incomplete inhibition of the" exact="virus infection" post="may enable selection of drug-resistant virus strains that can"/>
  <result pre="must be highly effective, as incomplete inhibition of the virus" exact="infection" post="may enable selection of drug-resistant virus strains that can"/>
  <result pre="cause an even greater threat. Accordingly, most anti-viral compounds target" exact="viral" post="enzymes, such as proteases12,35 and replication enzymes.36,37 New anti-viral"/>
  <result pre="cells and virion uncoating, inhibiting regulatory functions, or targeting the" exact="viral" post="RNA.38 Potential drugs with such activities can be identified"/>
  <result pre="drugs with such activities can be identified by using purified" exact="viral" post="proteins in high-throughput mechanism-based experimental screens. Computational approaches, based"/>
  <result pre="developing a number of agents to treat or inhibit human" exact="immunodeficiency" post="virus (HIV) infection, as well as anti-hepatitis C virus"/>
  <result pre="well as anti-hepatitis C virus (HCV) medications to bring about" exact="complete" post="cure, reinforces the belief that any viral disease can"/>
  <result pre="to bring about complete cure, reinforces the belief that any" exact="viral" post="disease can be effectively treated by specific, safe, and"/>
  <result pre="bring about complete cure, reinforces the belief that any viral" exact="disease" post="can be effectively treated by specific, safe, and effective"/>
  <result pre="at present there is no effective drug to treat SARS-CoV-2" exact="infection" post="or any other CoV. The emergence of COVID-19 highlights"/>
  <result pre="a variety of strategies to detect potential inhibitors of SARS-CoV-2" exact="infection" post="is expected to identify a large panel of potential"/>
  <result pre="in the development process. Finally, evaluation of the effectiveness of" exact="type I" post="interferon combinations, which is known to induce cellular anti-viral"/>
  <result pre="and new drugs, is warranted. PREVENTION AND VACCINE Vaccines against" exact="viral" post="diseases have been in use for hundreds of years"/>
  <result pre="does not induce immune memory. In the context of an" exact="acute" post="viral infection, such treatment involves administration of anti-viral antibodies"/>
  <result pre="not induce immune memory. In the context of an acute" exact="viral infection," post="such treatment involves administration of anti-viral antibodies that were"/>
  <result pre="either derived from the plasma of individuals who recovered from" exact="infection" post="or synthetically designed. Treatment can be provided during infection"/>
  <result pre="from infection or synthetically designed. Treatment can be provided during" exact="infection" post="or prophylactically to protect individuals at high risk such"/>
  <result pre="Transfusion of convalescent plasma was proven effective in treating several" exact="viral" post="infections including the H5N139 and H1N140 strains of influenza"/>
  <result pre="of convalescent plasma was proven effective in treating several viral" exact="infections" post="including the H5N139 and H1N140 strains of influenza virus"/>
  <result pre="beneficial to SARS-CoV-2,45,46 yet its effect on virus shedding and" exact="disease" post="outcome must be evaluated when given to healthy individuals"/>
  <result pre="severity of the disease. Importantly, diverse antibodies are produced following" exact="viral infection," post="yet only a fraction of these antibodies is capable"/>
  <result pre="infection. Accordingly, while convalescent plasma could be useful in the" exact="short" post="term, it is preferable to identify the most potent"/>
  <result pre="attenuated live viruses, inactivated viruses, recombinant viruses, recombinant or purified" exact="viral" post="proteins, or virion-like particles that mimic infectious virions. In"/>
  <result pre="recombinant or purified viral proteins, or virion-like particles that mimic" exact="infectious" post="virions. In all cases, the vaccine induces an immune"/>
  <result pre="various populations including the elderly who are more vulnerable to" exact="infection" post="but unfortunately mount lower responses to vaccines. An effective"/>
  <result pre="elderly who are more vulnerable to infection but unfortunately mount" exact="lower" post="responses to vaccines. An effective vaccine is one that"/>
  <result pre="one that induces an immune response that provides protection against" exact="infection" post="and pathogen-related disease. Ideally, a vaccine should provide life-long"/>
  <result pre="short-term vaccines may also be useful, at least during an" exact="intermediate" post="period until alternatives are available. A race to generate"/>
  <result pre="approaches involving RNA and DNA vaccines that enable production of" exact="viral" post="antigens upon injection are also being evaluated. A universal"/>
  <result pre="being evaluated. A universal coronavirus vaccine designed to target conserved" exact="viral" post="epitopes, most likely in the spike proteins, may enable"/>
  <result pre="as well as identifying other clues that may help understand" exact="viral" post="pathogenesis towards mitigating and combating COVID-19. Finally, by combining"/>
  <result pre="constant monitoring of the population to examine the incidence of" exact="infection" post="as well as the genetic shift of the virus"/>
  <result pre="may undergo genetic changes enabling them to infect humans. Whether" exact="infection" post="with one virus family member confers a certain level"/>
  <result pre="to this article was reported. Abbreviations CoV coronavirus COVID-19 coronavirus" exact="disease" post="2019 hCoV human coronavirus SARS severe acute respiratory syndrome."/>
  <result pre="coronavirus COVID-19 coronavirus disease 2019 hCoV human coronavirus SARS severe" exact="acute" post="respiratory syndrome. References REFERENCES 1GatesBThe next outbreak? Weâ€™re not"/>
  <result pre="COVID-19 coronavirus disease 2019 hCoV human coronavirus SARS severe acute" exact="respiratory" post="syndrome. References REFERENCES 1GatesBThe next outbreak? Weâ€™re not readyTED"/>
  <result pre="unansweredSci Transl Med201911eaau548510.1126/scitranslmed.aau548531341062 3KsiazekTGErdmanDGoldsmithCSet al.A novel coronavirus associated with severe" exact="acute" post="respiratory syndromeN Engl J Med200334819536610.1056/NEJMoa03078112690092 4PeirisJSYuenKYOsterhausADStohrKThe severe acute respiratory"/>
  <result pre="Transl Med201911eaau548510.1126/scitranslmed.aau548531341062 3KsiazekTGErdmanDGoldsmithCSet al.A novel coronavirus associated with severe acute" exact="respiratory" post="syndromeN Engl J Med200334819536610.1056/NEJMoa03078112690092 4PeirisJSYuenKYOsterhausADStohrKThe severe acute respiratory syndromeN"/>
  <result pre="with severe acute respiratory syndromeN Engl J Med200334819536610.1056/NEJMoa03078112690092 4PeirisJSYuenKYOsterhausADStohrKThe severe" exact="acute" post="respiratory syndromeN Engl J Med200334924314110.1056/NEJMra03249814681510 5RotaPAObersteMSMonroeSSet al.Characterization of a"/>
  <result pre="severe acute respiratory syndromeN Engl J Med200334819536610.1056/NEJMoa03078112690092 4PeirisJSYuenKYOsterhausADStohrKThe severe acute" exact="respiratory" post="syndromeN Engl J Med200334924314110.1056/NEJMra03249814681510 5RotaPAObersteMSMonroeSSet al.Characterization of a novel"/>
  <result pre="Med200334924314110.1056/NEJMra03249814681510 5RotaPAObersteMSMonroeSSet al.Characterization of a novel coronavirus associated with severe" exact="acute" post="respiratory syndromeScience20033001394910.1126/science.108595212730500 6ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus from"/>
  <result pre="5RotaPAObersteMSMonroeSSet al.Characterization of a novel coronavirus associated with severe acute" exact="respiratory" post="syndromeScience20033001394910.1126/science.108595212730500 6ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus from a"/>
  <result pre="6ZakiAMvan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med201236718142010.1056/NEJMoa121172123075143 7AssiriAMcGeerAPerlTMet al.Hospital outbreak"/>
  <result pre="ArabiaN Engl J Med201236718142010.1056/NEJMoa121172123075143 7AssiriAMcGeerAPerlTMet al.Hospital outbreak of Middle East" exact="respiratory" post="syndrome coronavirusN Engl J Med20133694071610.1056/NEJMoa130674223782161 8DecaroNLorussoANovel human coronavirus (SARS-CoV-2):"/>
  <result pre="Engl J Med201236718142010.1056/NEJMoa121172123075143 7AssiriAMcGeerAPerlTMet al.Hospital outbreak of Middle East respiratory" exact="syndrome" post="coronavirusN Engl J Med20133694071610.1056/NEJMoa130674223782161 8DecaroNLorussoANovel human coronavirus (SARS-CoV-2): a"/>
  <result pre="13SaifLJAnimal coronaviruses: what can they teach us about the severe" exact="acute" post="respiratory syndrome?Rev Sci Tech2004236436010.20506/rst.23.2.151315702725 14YeZWYuanSYuenKSFungSYChanCPJinDYZoonotic origins of human coronavirusesInt"/>
  <result pre="coronaviruses: what can they teach us about the severe acute" exact="respiratory" post="syndrome?Rev Sci Tech2004236436010.20506/rst.23.2.151315702725 14YeZWYuanSYuenKSFungSYChanCPJinDYZoonotic origins of human coronavirusesInt J"/>
  <result pre="al.Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by" exact="complete" post="genome sequencingPLoS Pathog20106e100089610.1371/journal.ppat.100089620463816 18TyrrellDABynoeMLCultivation of viruses from a high"/>
  <result pre="patients with coldsLancet1966176710.1016/s0140-6736(66)92364-64158999 19HamreDProcknowJJA new virus isolated from the human" exact="respiratory" post="tractProc Soc Exp Biol Med1966121190310.3181/00379727-121-307344285768 20McIntoshKDeesJHBeckerWBKapikianAZChanockRMRecovery in tracheal organ"/>
  <result pre="in tracheal organ cultures of novel viruses from patients with" exact="respiratory" post="diseaseProc Natl Acad Sci U S A1967579334010.1073/pnas.57.4.9335231356 21WooPCLauSKChuCMet al.Characterization"/>
  <result pre="diseaseProc Natl Acad Sci U S A1967579334010.1073/pnas.57.4.9335231356 21WooPCLauSKChuCMet al.Characterization and" exact="complete" post="genome sequence of a novel coronavirus, coronavirus HKU1, from"/>
  <result pre="Dis200519149950210.1086/42829115655771 24ShimizuCShikeHBakerSCet al.Human coronavirus NL63 is not detected in the" exact="respiratory" post="tracts of children with acute Kawasaki diseaseJ Infect Dis200519217677110.1086/49717016235175"/>
  <result pre="is not detected in the respiratory tracts of children with" exact="acute" post="Kawasaki diseaseJ Infect Dis200519217677110.1086/49717016235175 25LehmannCKlarRLindnerJLindnerPWolfHGerlingSKawasaki disease lacks association with"/>
  <result pre="tracts of children with acute Kawasaki diseaseJ Infect Dis200519217677110.1086/49717016235175 25LehmannCKlarRLindnerJLindnerPWolfHGerlingSKawasaki" exact="disease" post="lacks association with human coronavirus NL63 and human bocavirusPediatr"/>
  <result pre="and coronavirus infectionsSemin Respir Crit Care Med2016375557110.1055/s-0036-158479727486736 28FriedmanNAlterHHindiyehMMendelsonEShemer AvniYMandelboimMHuman coronavirus" exact="infections" post="in Israel: epidemiology, clinical symptoms and summer seasonality of"/>
  <result pre="seasonality of HCoV-HKU1Viruses20181051510.3390/v10100515 29PatrickDMPetricMSkowronskiDMet al.An outbreak of human coronavirus OC43" exact="infection" post="and serological cross-reactivity with SARS coronavirusCan J Infect Dis"/>
  <result pre="their recombination historyJ Virol201791e019531610.1128/JVI.01953-1628077633 31LorussoADesarioCMariVet al.Molecular characterization of a canine" exact="respiratory" post="coronavirus strain detected in ItalyVirus Res20091419610010.1016/j.virusres.2008.12.01119162098 32ShiJWenZZhongGet al.Susceptibility of"/>
  <result pre="potential therapeutic targetIntensive Care Med2020465869010.1007/s00134-020-05985-932125455 34ChengMPPapenburgJDesjardinsMet al.Diagnostic testing for severe" exact="acute" post="respiratory syndrome-related coronavirus 2: a narrative reviewAnn Intern Med20201727263410.7326/M20-130132282894"/>
  <result pre="therapeutic targetIntensive Care Med2020465869010.1007/s00134-020-05985-932125455 34ChengMPPapenburgJDesjardinsMet al.Diagnostic testing for severe acute" exact="respiratory" post="syndrome-related coronavirus 2: a narrative reviewAnn Intern Med20201727263410.7326/M20-130132282894 35DaiWZhangBJiangXMet"/>
  <result pre="42van GriensvenJEdwardsTde LamballerieXet al.Evaluation of convalescent plasma for Ebola virus" exact="disease" post="in GuineaN Engl J Med2016374334210.1056/NEJMoa151181226735992 43FlorescuDFKalilACHewlettALet al.Administration of brincidofovir"/>
  <result pre="effects of convalescent plasma therapy for patients with Middle East" exact="respiratory" post="syndrome coronavirus infection: a study protocolSpringerplus2015470910.1186/s40064-015-1490-926618098 45ShenCWangZZhaoFet al.Treatment of"/>
  <result pre="of convalescent plasma therapy for patients with Middle East respiratory" exact="syndrome" post="coronavirus infection: a study protocolSpringerplus2015470910.1186/s40064-015-1490-926618098 45ShenCWangZZhaoFet al.Treatment of 5"/>
 </snippets>
</snippetsTree>
